From GlobeNewswire:

Vaxcyte Inc. announced the pricing of a public offering of 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares. This offering is expected to close on February 2 and will raise approximately $750.0 million. The underwriters have a 30-day option to purchase an additional 1,757,812 shares of the company’s common stock at the public offering price. Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from bacterial diseases. It’s developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases, such as its lead candidate, VAX-24, and its next-generation candidate, VAX-31. The company also has a pipeline that includes vaccines designed to prevent Group A Strep infections and periodontal disease.

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It’s developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases, such as its lead candidate, VAX-24, and its next-generation candidate, VAX-31. The company also has a pipeline that includes vaccines designed to prevent Group A Strep infections and periodontal disease.



Read more: Vaxcyte Announces Pricing of $750 Million Public Offering